T1	CHEM 285 289	FAME
#1	AnnotatorNotes T1	C0242708; Antirheumatic Drugs, Disease-Modifying; Pharmacologic Substance
T2	PROC 86 93	placebo
#2	AnnotatorNotes T2	C0032042; Placebos; Therapeutic or Preventive Procedure
T3	DISO 111 130	artritis psoriásica
#3	AnnotatorNotes T3	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T4	DISO 780 814	parches escamosos rojos en la piel
T5	PROC 2051 2058	tratado
#4	AnnotatorNotes T5	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T6	CHEM 232 283	fármaco antirreumático modificador de la enfermedad
#5	AnnotatorNotes T6	C0242708; Antirheumatic Drugs, Disease-Modifying; Pharmacologic Substance
T7	PROC 313 354	Estudio fase 3, aleatorizado, doble ciego
T8	PROC 390 397	placebo
#6	AnnotatorNotes T8	C0032042; Placebos; Therapeutic or Preventive Procedure
T9	DISO 415 434	artritis psoriásica
#7	AnnotatorNotes T9	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T10	CHEM 589 593	FAME
#8	AnnotatorNotes T10	C0242708; Antirheumatic Drugs, Disease-Modifying; Pharmacologic Substance
T11	CHEM 536 587	fármaco antirreumático modificador de la enfermedad
#9	AnnotatorNotes T11	C0242708; Antirheumatic Drugs, Disease-Modifying; Pharmacologic Substance
T12	ANAT 664 675	sist inmune
T13	DISO 631 654	enfermedad inflamatoria
T14	ANAT 688 702	articulaciones
#10	AnnotatorNotes T14	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T15	ANAT 716 720	piel
#11	AnnotatorNotes T15	C1123023; Skin; Body System | C1278993; Entire skin; Body System
T16	DISO 737 746	hinchazón
#12	AnnotatorNotes T16	C0038999; Swelling; Finding
T17	DISO 748 777	rigidez en las articulaciones
#13	AnnotatorNotes T17	C0162298; Joint stiffness; Sign or Symptom
T18	ANAT 788 797	escamosos
#14	AnnotatorNotes T18	C0221909; Squamous epithelium; Tissue
T19	ANAT 810 814	piel
#15	AnnotatorNotes T19	C1123023; Skin; Body System | C1278993; Entire skin; Body System
T20	DISO 841 860	Artritis Psoriásica
#16	AnnotatorNotes T20	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T21	PROC 889 908	Diagnóstico clínico
#17	AnnotatorNotes T21	C0332140; Diagnosis, clinical; Diagnostic Procedure
T22	DISO 937 945	síntomas
#18	AnnotatorNotes T22	C1457887; Symptoms; Sign or Symptom
T23	DISO 1115 1125	enfermedad
#19	AnnotatorNotes T23	C0012634; Disease; Disease or Syndrome
T24	PROC 1169 1180	Diagnóstico
#20	AnnotatorNotes T24	C0011900; Diagnosis; Diagnostic Procedure
T25	DISO 1184 1203	psoriasis en placas
#21	AnnotatorNotes T25	C0263361; Psoriasis vulgaris; Disease or Syndrome
T26	DISO 912 915	APs
#22	AnnotatorNotes T26	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T27	DISO 1052 1055	APs
#23	AnnotatorNotes T27	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T28	DISO 1228 1244	placa psoriásica
T29	DISO 1266 1288	alteraciones ungueales
T30	DISO 1305 1314	psoriasis
#24	AnnotatorNotes T30	C0033860; Psoriasis; Disease or Syndrome
T31	CHEM 1766 1773	FARMEsc
#25	AnnotatorNotes T31	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance (?) [fármaco modificador de enfermedad sintético convencional, 'conventional synthetic disease-modifying antirheumatic drugs (DMARD)']
T32	PROC 1559 1564	hsCRP
#26	AnnotatorNotes T32	C4763419; High Sensitivity C-Reactive Protein Measurement; Laboratory Procedure
T33	DISO 1417 1424	erosión
#27	AnnotatorNotes T33	C1959609; Erosion lesion; Pathologic Function
T34	PROC 1478 1510	revisión central de las imágenes
T35	CHEM 1517 1527	Proteína C
#28	AnnotatorNotes T35	C0033621; protein C; Amino Acid, Peptide, or Protein · Biologically Active Substance · Pharmacologic Substance
T36	PROC 1642 1653	tratamiento
#29	AnnotatorNotes T36	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T37	CHEM 2015 2027	Risankizumab
#30	AnnotatorNotes T37	C4505511; risankizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T38	DISO 1986 2003	hipersensibilidad
#31	AnnotatorNotes T38	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T39	PROC 2075 2092	terapia biológica
#32	AnnotatorNotes T39	C0005527; Biological Response Modifier Therapy; Therapeutic or Preventive Procedure
T40	CHEM 64 76	risankizumab
#33	AnnotatorNotes T40	C4505511; risankizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T41	DISO 132 134	AP
#34	AnnotatorNotes T41	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T42	DISO 205 217	intolerancia
#35	AnnotatorNotes T42	C0277585; Intolerance to drug; Pathologic Function
T43	CHEM 368 380	risankizumab
#36	AnnotatorNotes T43	C4505511; risankizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T44	DISO 436 438	AP
#37	AnnotatorNotes T44	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T45	DISO 509 521	intolerancia
#38	AnnotatorNotes T45	C0277585; Intolerance to drug; Pathologic Function
T46	DISO 621 623	AP
#39	AnnotatorNotes T46	C0003872; Arthritis, Psoriatic; Disease or Syndrome
T47	DISO 730 735	dolor
#40	AnnotatorNotes T47	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T48	ANAT 763 777	articulaciones
#41	AnnotatorNotes T48	C0022417; Joints; Body Space or Junction | C1269611; Entire joint; Body Space or Junction
T49	ANAT 1279 1288	ungueales
#42	AnnotatorNotes T49	C0027342; Nail plate; Body Part, Organ, or Organ Component
T50	PROC 1517 1557	Proteína C-reactiva de alta sensibilidad
T51	CHEM 1685 1692	FARMEsc
#43	AnnotatorNotes T51	C4054347; Non-Biologic Disease-Modifying Antirheumatic Drug; Pharmacologic Substance (?) [fármaco modificador de enfermedad sintético convencional, 'conventional synthetic disease-modifying antirheumatic drugs (DMARD)']
T52	DISO 1718 1730	intolerancia
#44	AnnotatorNotes T52	C0277585; Intolerance to drug; Pathologic Function
T53	Date 12 16	2017
T54	LIVB 97 106	pacientes
#45	AnnotatorNotes T54	C0030705; Patients; Patient or Disabled Group
T55	LIVB 401 410	pacientes
#46	AnnotatorNotes T55	C0030705; Patients; Patient or Disabled Group
T58	Duration 946 962	al menos 6 meses
T59	LIVB 1098 1107	pacientes
#47	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T63	LIVB 1583 1591	paciente
#48	AnnotatorNotes T63	C0030705; Patients; Patient or Disabled Group
T64	Date 1663 1669	actual
T65	LIVB 1698 1706	paciente
#49	AnnotatorNotes T65	C0030705; Patients; Patient or Disabled Group
T66	LIVB 1802 1814	investigador
#50	AnnotatorNotes T66	C0035173; Research Personnel; Professional or Occupational Group
T67	LIVB 1847 1855	paciente
#51	AnnotatorNotes T67	C0030705; Patients; Patient or Disabled Group
T68	LIVB 1878 1900	investigador principal
#52	AnnotatorNotes T68	C1521895; Principal Investigator; Professional or Occupational Group
T70	LIVB 1967 1975	paciente
#53	AnnotatorNotes T70	C0030705; Patients; Patient or Disabled Group
T71	LIVB 2034 2042	paciente
#54	AnnotatorNotes T71	C0030705; Patients; Patient or Disabled Group
T56	DISO 273 283	enfermedad
#55	AnnotatorNotes T56	C0012634; Disease; Disease or Syndrome
T57	DISO 577 587	enfermedad
#56	AnnotatorNotes T57	C0012634; Disease; Disease or Syndrome
T60	PROC 1436 1452	radiológicamente
#57	AnnotatorNotes T60	C0043299; Diagnostic radiologic examination; Diagnostic Procedure | C1962945; Radiographic imaging procedure; Diagnostic Procedure
T61	PROC 1153 1159	visita
#58	AnnotatorNotes T61	C1512346; Patient Visit; Health Care Activity
T62	Quantifier_or_Qualifier 1160 1165	basal
#59	AnnotatorNotes T62	C1442488; Baseline; Quantitative Concept
T69	PROC 975 994	visita de selección
#60	AnnotatorNotes T69	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T72	PROC 1071 1090	visita de selección
#61	AnnotatorNotes T72	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
T73	PROC 1321 1340	visita de selección
#62	AnnotatorNotes T73	C1710477; Trial Screening; Research Activity + C1512346; Patient Visit; Health Care Activity
A1	Status T42 History_of
A2	Status T45 History_of
A3	Status T6 History_of
A4	Status T1 History_of
A5	Status T11 History_of
A6	Status T10 History_of
A7	Status T36 History_of
A8	Status T51 History_of
A9	Assertion T31 Contraindicated
A10	Status T38 History_of
A11	Status T5 History_of
A12	Status T39 History_of
#63	AnnotatorNotes T7	C0282461; Phase 3 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity
#64	AnnotatorNotes T13	C1290884; Inflammatory disorder; Disease or Syndrome 
#65	AnnotatorNotes T12	C0020962; Immune system; Body System
#66	AnnotatorNotes T28	C0920235; Psoriatic plaque; Disease or Syndrome 
#67	AnnotatorNotes T50	C4763419; High Sensitivity C-Reactive Protein Measurement; Laboratory Procedure
#68	AnnotatorNotes T64	C0521116; Current (present time); Temporal Concept 
T74	Observation 1936 1960	adecuado para el estudio
A13	Assertion T74 Negated
#69	AnnotatorNotes T74	C1302261; Patient eligible for clinical trial; Finding (?)
T75	Neg_cue 1933 1935	no
R1	Experiences Arg1:T54 Arg2:T40	
R2	Experiences Arg1:T54 Arg2:T2	
R3	Experiences Arg1:T54 Arg2:T3	
R4	Experiences Arg1:T54 Arg2:T41	
T76	Quantifier_or_Qualifier 136 142	activa
#70	AnnotatorNotes T76	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R5	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T76	
R6	Has_Quantifier_or_Qualifier Arg1:T41 Arg2:T76	
R7	Causes Arg1:T6 Arg2:T42	
R8	Causes Arg1:T1 Arg2:T42	
T77	Observation 486 506	respuesta inadecuada
A14	Status T77 History_of
#71	AnnotatorNotes T77	C0858218; Inappropriate drug response; Finding
R9	Overlap Arg1:T77 Arg2:T11	
T78	Observation 182 202	respuesta inadecuada
A15	Status T78 History_of
#72	AnnotatorNotes T78	C0858218; Inappropriate drug response; Finding
R10	Overlap Arg1:T78 Arg2:T6	
R11	Overlap Arg1:T78 Arg2:T1	
R12	Experiences Arg1:T54 Arg2:T78	
R13	Experiences Arg1:T54 Arg2:T42	
R15	Experiences Arg1:T54 Arg2:T56	
R18	Before Arg1:T6 Arg2:T40	
R19	Before Arg1:T1 Arg2:T40	
R20	Before Arg1:T6 Arg2:T2	
R17	Before Arg1:T1 Arg2:T2	
R21	Experiences Arg1:T55 Arg2:T43	
R22	Experiences Arg1:T55 Arg2:T8	
R23	Experiences Arg1:T55 Arg2:T9	
R24	Experiences Arg1:T55 Arg2:T44	
T79	Quantifier_or_Qualifier 440 446	activa
#73	AnnotatorNotes T79	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R25	Has_Quantifier_or_Qualifier Arg1:T44 Arg2:T79	
R26	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T79	
R27	Experiences Arg1:T55 Arg2:T77	
R28	Experiences Arg1:T55 Arg2:T45	
R31	Experiences Arg1:T55 Arg2:T57	
R32	Overlap Arg1:T77 Arg2:T10	
R33	Causes Arg1:T11 Arg2:T45	
R34	Causes Arg1:T10 Arg2:T45	
R35	Before Arg1:T11 Arg2:T43	
R36	Before Arg1:T11 Arg2:T8	
R37	Before Arg1:T10 Arg2:T43	
R38	Before Arg1:T10 Arg2:T8	
R39	Location_of Arg1:T14 Arg2:T13	
R40	Location_of Arg1:T14 Arg2:T46	
R41	Location_of Arg1:T15 Arg2:T13	
R42	Location_of Arg1:T15 Arg2:T46	
T80	Quantifier_or_Qualifier 703 708	sanas
#74	AnnotatorNotes T80	C3898900; Healthy; Qualitative Concept
R43	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T80	
R44	Location_of Arg1:T14 Arg2:T47	
R45	Location_of Arg1:T14 Arg2:T16	
R46	Location_of Arg1:T48 Arg2:T17	
R47	Location_of Arg1:T19 Arg2:T4	
R48	Causes Arg1:T46 Arg2:T47	
R49	Causes Arg1:T46 Arg2:T16	
R50	Causes Arg1:T46 Arg2:T17	
R51	Causes Arg1:T46 Arg2:T4	
R52	Causes Arg1:T26 Arg2:T22	
R53	Has_Duration_or_Interval Arg1:T22 Arg2:T58	
R54	Before Arg1:T22 Arg2:T69	
R55	Before Arg1:T21 Arg2:T69	
R56	Causes Arg1:T27 Arg2:T22	
T81	CONC 1017 1064	Criterios de clasificación para la APs (CASPAR)
R57	Used_for Arg1:T81 Arg2:T21	
R60	Has_Quantifier_or_Qualifier Arg1:T61 Arg2:T62	
R61	Experiences Arg1:T59 Arg2:T23	
T82	Quantifier_or_Qualifier 1126 1132	activa
#75	AnnotatorNotes T82	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R62	Has_Quantifier_or_Qualifier Arg1:T23 Arg2:T82	
T83	Quantifier_or_Qualifier 1204 1210	activa
#76	AnnotatorNotes T83	C0205177; Active; Qualitative Concept | C0679217; Active State; Idea or Concept
R63	Has_Quantifier_or_Qualifier Arg1:T25 Arg2:T83	
T84	Quantifier_or_Qualifier 1215 1227	al menos una
R64	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T84	
T85	Result_or_Value 1245 1251	≥ 2 cm
R65	Has_Result_or_Value Arg1:T28 Arg2:T85	
R66	Location_of Arg1:T49 Arg2:T29	
#77	AnnotatorNotes T29	C0234909; Nail changes; Finding
R67	Overlap Arg1:T29 Arg2:T30	
R68	Overlap Arg1:T29 Arg2:T73	
R69	Overlap Arg1:T30 Arg2:T73	
T86	Quantifier_or_Qualifier 1413 1416	≥ 1
R70	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T86	
T87	Result_or_Value 1566 1576	≥ 3,0 mg/l
R73	Has_Result_or_Value Arg1:T32 Arg2:T87	
R74	Has_Result_or_Value Arg1:T50 Arg2:T87	
T88	Observation 1616 1638	respuesta insuficiente
A16	Status T88 History_of
#78	AnnotatorNotes T88	C0858218; Inappropriate drug response; Finding
R75	Overlap Arg1:T88 Arg2:T36	
R76	Experiences Arg1:T63 Arg2:T88	
R77	Experiences Arg1:T63 Arg2:T36	
R78	Overlap Arg1:T36 Arg2:T64	
T89	Quantifier_or_Qualifier 1674 1684	al menos 1
R79	Has_Quantifier_or_Qualifier Arg1:T51 Arg2:T89	
R80	Used_for Arg1:T51 Arg2:T36	
R81	Experiences Arg1:T65 Arg2:T52	
R82	Experiences Arg1:T65 Arg2:T88	
R83	Experiences Arg1:T65 Arg2:T36	
R84	Experiences Arg1:T63 Arg2:T52	
R85	Causes Arg1:T31 Arg2:T52	
R88	Has_Quantifier_or_Qualifier Arg1:T67 Arg2:T74	
R89	Negation Arg1:T75 Arg2:T74	
R90	Experiences Arg1:T70 Arg2:T38	
R91	Causes Arg1:T37 Arg2:T38	
R92	Experiences Arg1:T71 Arg2:T5	
R93	Experiences Arg1:T71 Arg2:T39	
R58	Overlap Arg1:T81 Arg2:T72	
R14	Overlap Arg1:T23 Arg2:T61	
R16	Overlap Arg1:T25 Arg2:T28	
R29	Overlap Arg1:T25 Arg2:T29	
R30	Overlap Arg1:T25 Arg2:T73	
A17	Experiencer T63 Patient
A18	Experiencer T54 Patient
A19	Experiencer T55 Patient
A20	Experiencer T59 Patient
A21	Experiencer T65 Patient
A22	Experiencer T66 Other
A23	Experiencer T68 Other
A24	Experiencer T67 Patient
A25	Experiencer T70 Patient
A26	Experiencer T71 Patient
